Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 10/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13834810 | 0.99 | TPSAB1 (0.55) | TPSAB1CYP3A4CYP2D6KCNH2CA12 | |
| SCHEMBL14882330 | 0.91 | TPSAB1 (0.54) | TPSAB1CYP3A4CYP2D6KCNH2CA12 | |
| SCHEMBL14882331 | 0.91 | TPSAB1 (0.54) | TPSAB1CYP3A4CYP2D6KCNH2CA12 | |
| SCHEMBL14882332 | 0.90 | TPSAB1 (0.56) | TPSAB1CYP3A4CYP2D6KCNH2 | |
| SCHEMBL14882187 | 0.90 | TPSAB1 (0.53) | TPSAB1CYP3A4CYP2D6KCNH2CA12 | |
| SCHEMBL14882188 | 0.90 | TPSAB1 (0.53) | TPSAB1CYP3A4CYP2D6KCNH2CA12 | |
| SCHEMBL14882189 | 0.90 | TPSAB1 (0.56) | TPSAB1CYP3A4CYP2D6KCNH2 | |
| SCHEMBL13830737 | 0.89 | TPSAB1 (0.57) | TPSAB1CYP3A4CYP2D6KCNH2 | |
| SCHEMBL15866715 | 0.89 | TOP1 (0.47) | TPSAB1CYP3A4CYP2D6KCNH2 | |
| SCHEMBL14898152 | 0.89 | TPSAB1 (0.55) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | claimed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | MYOF, FTH1, HCCS | TPSAB1 4615/4885CYP3A4 1275/4885CYP2D6 322/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | TPSAB1 4326/4885CYP3A4 4816/4885CYP2D6 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.